BHVN · Biohaven Ltd.
AI read · Good for BHVN
The AI's read
The responses give Biohaven an encouraging early sign that BHV-1530 may help people with FGFR3-altered tumors. No dose-limiting reactions or treatment-related deaths were reported. But the results cover only 10 evaluable patients, and the company plans to start a pivotal study as early as the first half of 2027. The findings are promising, but they do not show that the drug will win approval.